The study, spearheaded by researchers Klawans, Benjamin, Maroufy, and their colleagues, delves into a complex interplay of factors influencing fetal development amidst maternal cannabis consumption. By leveraging an extensive dataset drawn from the National Birth Defects Prevention Study, the team undertook a rigorous epidemiologic analysis to elucidate potential causative pathways between cannabis exposure and negative birth outcomes. This large-scale cohort provides a robust framework to control for confounding variables, allowing for a more precise determination of cannabis’s effects.

One of the primary concerns addressed by the investigation is the correlation between cannabis use during pregnancy and the incidence of preterm birth—a leading cause of neonatal morbidity and mortality worldwide. Preterm birth, defined as delivery prior to 37 completed weeks of gestation, has multifactorial etiology, with substance use emerging as a modifiable risk factor. The study’s data suggest that prenatal cannabis exposure may elevate the risk of preterm delivery, an outcome with profound implications for neonatal intensive care utilization and long-term child development.

Equally consequential is the study’s examination of small for gestational age infants, a condition characterized by fetal growth restriction resulting in birth weights below the 10th percentile for gestational age. SGA status is intimately linked with increased susceptibility to perinatal complications and chronic health issues later in life such as metabolic syndrome and cardiovascular disease. The researchers’ findings indicate a statistically significant association between maternal cannabis use and the incidence of SGA newborns, prompting questions regarding the underlying biological mechanisms at play.

Cannabis exerts its physiological effects primarily through interactions with the endocannabinoid system, which plays a critical regulatory role in neurodevelopment and placental function. Delta-9-tetrahydrocannabinol (THC), the principal psychoactive compound in cannabis, readily crosses the placental barrier and may interfere with normal fetal growth trajectories. Additionally, cannabinoid receptor activation can modulate blood flow and nutrient transport within the placenta, potentially explaining observed growth restrictions in exposed fetuses.

The methodological approach employed in this investigation is noteworthy for its rigorous stratification of cannabis exposure, timing during pregnancy, and dosage estimates, enhancing the granularity of the conclusions drawn. Such detailed exposure assessments are essential for disentangling the effect sizes attributable to varying patterns of cannabis use, ranging from occasional to chronic consumption. Moreover, the control for concomitant exposure to other substances such as tobacco and alcohol strengthens the study’s validity.

Importantly, the research emphasizes the temporal vulnerability of the developing fetus, noting that cannabis exposure during the first and second trimester may bear different risks compared to later gestational periods. This temporal stratification aligns with developmental milestones in organogenesis and fetal growth, reinforcing the need for temporally specific guidelines in prenatal counseling.

While observational studies inherently grapple with residual confounding, the convergence of epidemiological data with known pharmacological actions of cannabinoids lends credence to the causal inferences posited. The study’s comprehensive sensitivity analyses demonstrate robustness of results across various analytical models, underscoring the pressing need for clinicians to integrate cannabis exposure screening into routine prenatal care.

Public health messaging must adapt rapidly in light of these findings. The perception of cannabis as a benign or therapeutic agent during pregnancy must be recalibrated to reflect emerging evidence of potential harm. This recalibration is particularly urgent given the accelerated trends in legalization and decriminalization, which risk inadvertently promoting cannabis as a safe option for pregnant individuals.

The policy implications stemming from this research are multifaceted. Healthcare providers require updated training to competently address cannabis use during gestation, engaging in non-judgmental dialogue to identify and mitigate risk. Simultaneously, policymakers must consider regulatory frameworks that incorporate warnings about cannabis use in pregnancy as part of consumer education and product labeling mandates.

In parallel, the study’s findings reignite scientific discussions on the need for mechanistic studies exploring fetal cannabinoid receptor signaling pathways. Translational research leveraging animal models and placental tissue studies could unravel the molecular underpinnings of cannabis-induced growth restriction, paving the way for targeted interventions to offset detrimental outcomes.

Moreover, the research opens avenues to explore the intersectionality of cannabis exposure with socioeconomic determinants of health. Disparities in access to prenatal care and social support may exacerbate the risks associated with cannabis consumption during pregnancy, necessitating integrative approaches encompassing social, behavioral, and biological dimensions.

Critically, the National Birth Defects Prevention Study’s data illuminate the importance of longitudinal surveillance. Tracking exposed infants over time will be essential to ascertain the full spectrum of developmental, cognitive, and behavioral sequelae potentially linked to prenatal cannabis exposure. Such cohort studies could inform strategies for early interventions tailored to vulnerable populations.

Finally, this body of research serves as a clarion call to the scientific community regarding the evolving landscape of substance use and reproductive health. It highlights the imperative for interdisciplinary collaboration bridging obstetrics, neonatology, toxicology, neurodevelopment, and public health to address complex challenges posed by cannabis in pregnancy.

As cannabis becomes embedded within societal norms, the stewardship of maternal and infant health demands vigilance and proactive inquiry. The current study thus marks a significant advance in our understanding of how prenatal cannabis exposure shapes birth outcomes, setting the stage for future investigations and informed clinical practices aimed at safeguarding the next generation’s health.

Subject of Research: Impact of in utero cannabis exposure on birth outcomes, specifically preterm birth and small for gestational age infants.

Article Title: Cannabis use, preterm birth, and small for gestational age: findings from the national birth defects prevention study.

Article References:
Klawans, M.R., Benjamin, R.H., Maroufy, V. et al. Cannabis use, preterm birth, and small for gestational age: findings from the national birth defects prevention study. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02729-3

Image Credits: AI Generated

DOI: 27 May 2026

Cannabis use among pregnant individuals has become more common in recent years, notably diverging from declining trends in prenatal alcohol and tobacco consumption. Many expecting mothers perceive cannabis to be safe, particularly as it often replaces substances like nicotine and alcohol that they consciously quit. However, Dr. Lo highlights the critical disconnect between perception and evidence: the lingering federal classification of cannabis as a Schedule 1 substance contributes to a paucity of conclusive clinical data, creating a cloud of misinformation. This systemic review sought to address these uncertainties by rigorously evaluating the latest research evidence.

A striking facet of the updated meta-analysis is its enhanced methodological rigor and scope. The inclusion of eight recent studies since the previous review has elevated the confidence level regarding some adverse outcomes from “very low-to-low” to “moderate.” In particular, the evidence now more robustly supports associations between prenatal cannabis use and suboptimal neonatal outcomes such as low birth weight, premature delivery, and small-for-gestational-age infants. Though findings linking cannabis to neonatal mortality are still tentative, they raise important flags for ongoing investigation and clinical vigilance.

One challenge this research aims to circumvent is confounding from polysubstance use, especially nicotine, which often accompanies cannabis smoking. In this updated analysis, a substantial portion of included studies specifically examined populations that used cannabis in isolation, allowing a clearer attribution of effects to cannabis itself. This nuance is particularly relevant given preexisting knowledge about nicotine’s harms, helping to isolate cannabis’s independent impact on fetal development and birth outcomes.

A parallel body of research in nonhuman primates strengthens the biological plausibility of these human findings. Experimental prenatal exposure to tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, has been shown to impair placental function. Advanced imaging modalities, including ultrasound and MRI, reveal compromised placental blood flow and reduced oxygen delivery in exposed subjects, accompanied by decreased amniotic fluid volume. These physiological disruptions provide a mechanistic framework linking cannabis exposure to impaired fetal growth and development.

Dr. Lo emphasizes the critical role of the placenta as more than a passive conduit; it functions dynamically to regulate the intrauterine environment. Impairment of placental function can jeopardize nutrient and oxygen supply, with cascading effects on fetal viability and long-term health. These emerging data underscore the need for obstetricians to counsel patients not only on abstinence from cannabis but also on harm reduction strategies when complete cessation proves elusive.

Despite federal legal restrictions, multiple states including Oregon have legalized cannabis for both medical and recreational use, creating a complex regulatory and clinical landscape. This dichotomy contributes to mixed messages for pregnant individuals, many of whom report symptomatic relief from nausea, insomnia, and pain through cannabis use. Recognizing these competing pressures, Dr. Lo advocates a pragmatic approach that prioritizes reducing frequency and quantity, aiming to diminish risk while acknowledging patient realities.

The broader sociocultural context of cannabis legalization and normalization adds further layers of complexity. The absence of uniform public health messaging and standardized guidelines leaves many providers and patients navigating ambiguous terrain. This systematic review endeavors to fill critical evidence gaps, furnishing the medical community with more definitive data to inform risk communication and prenatal care protocols.

Financial support for this research was provided by the U.S. Department of Veterans Affairs’ Office of Rural Health and the National Institute on Drug Abuse, underscoring the cross-institutional commitment to understanding drug exposure during pregnancy. The investigation is also part of the Systematically Testing the Evidence on Marijuana (STEM) project, which strives to clarify the impact of cannabis use on health outcomes through comprehensive research synthesis.

As discourse around cannabis continues to evolve, this study prompts essential reevaluation of its safety profile in vulnerable populations. The demonstrated associations with adverse neonatal indicators highlight an urgent need for healthcare providers to proactively address cannabis use in prenatal counseling sessions. Creation of guidelines balancing patient autonomy with fetal safety will be pivotal in mitigating risks identified by this robust body of evidence.

Ultimately, this updated systematic review presents a cautionary message to both clinicians and expectant mothers: while cannabis may offer relief from pregnancy-related discomforts, its use is far from benign. The intricate interplay between cannabis exposure, placental function, and neonatal health demands ongoing investigation and nuanced clinical strategies. This research is a seminal step toward dispelling misconceptions and fostering informed decision-making in maternal-fetal medicine.

Subject of Research: People

Article Title: Prenatal Cannabis Use and Neonatal Outcomes; A Systematic Review and Meta-Analysis

News Publication Date: 5-May-2025

Web References:
https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.0689

References:
Lo, J., Yaddala, S., Shaw, B., Robalino, S., Ayers, C., Ward, R., & Kansagara, D. (2025). Prenatal Cannabis Use and Neonatal Outcomes; A Systematic Review and Meta-Analysis. JAMA Pediatrics. DOI: 10.1001/jamapediatrics.2025.0689

Keywords: Cannabis, Human reproduction, Gestational age